Black bile: Are elevated monoamines an etiological factor in some cases of major depression?

Medical Hypotheses

Volumn 80, Issue 6, 2013, Pages 823-826

  Fitzgerald, Paul J ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; DOPAMINE; FLUOXETINE; METOPROLOL; MONOAMINE; PROPRANOLOL; REBOXETINE; SEROTONIN; TIANEPTINE;

ARTICLE; ATYPICAL DEPRESSION; BIPOLAR DEPRESSION; CATECHOLAMINERGIC SYSTEM; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; MENTAL STRESS; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM;

DEPRESSIVE DISORDER, MAJOR; DOPAMINE; HUMANS; MODELS, BIOLOGICAL; NOREPINEPHRINE; SEROTONIN; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

MUS; RODENTIA;

EID: 84877128909     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.03.023     Document Type: Article

References (52)

1. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122:509-522.
2. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 1967, 113:1237-1264.
3. Richelson E. Synaptic effects of antidepressants. J. Clin. Psychopharmacol. 1996, 16:1S-7S.
4. Koenig A.M., Thase M.E. First-line pharmacotherapies for depression - what is the best choice?. Pol. Arch. Med. Wewn. 2009, 119:478-486.
5. Janowsky D.S., el-Yousef M.K., Davis J.M., Sekerke H.J. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972, 2:632-635.
6. Jimerson D.C., Nurnberger J.I., Post R.M., Gershon E.S., Kopin I.J. Plasma MHPG in rapid cyclers and healthy twins. Arch. Gen. Psychiatry 1981, 38:1287-1290.
7. Massart R., Mongeau R., Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367:2485-2494.
8. Shaw D.M., O'Keeffe R., MacSweeney D.A., Brooksbank B.W., Noguera R., Coppen A. 3-Methoxy-4-hydroxyphenylglycol in depression. Psychol. Med. 1973, 3:333-336.
9. Coppen A., Rama Rao V.A., Ruthven C.R., Goodwin B.L., Sandler M. Urinary 4-hydroxy-3-methoxyphenylglycol is not a predictor for clinical response to amitriptyline in depressive illness. Psychopharmacology (Berl.) 1979, 64:95-97.
10. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5:e45.
11. Hajos-Korcsok E., Robinson D.D., Yu J.H., Fitch C.S., Walker E., Merchant K.M. Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeated footshock stress in rats. Pharmacol. Biochem. Behav. 2003, 74:609-616.
12. Mathews T.A., Fedele D.E., Coppelli F.M., Avila A.M., Murphy D.L., Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 2004, 140:169-181.
13. Lira A., Zhou M., Castanon N., Ansorge M.S., Gordon J.A., Francis J.H., et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 2003, 54:960-971.
14. Ihne J.L., Fitzgerald P.J., Hefner K.R., Holmes A. Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice. Neuropharmacology 2012, 62:464-473.
15. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
16. Gonda X., Juhasz G., Laszik A., Rihmer Z., Bagdy G. Subthreshold depression is linked to the functional polymorphism of the 5HT transporter gene. J. Affect. Disord. 2005, 87:291-297.
17. Steffens D.C., Svenson I., Marchuk D.A., Levy R.M., Hays J.C., Flint E.P., et al. Allelic differences in the serotonin transporter-linked polymorphic region in geriatric depression. Am. J. Geriatr. Psychiatry 2002, 10:185-191.
18. Whitton P.S., Sarna G.S., O'Connell M.T., Curzon G. The effect of the novel antidepressant tianeptine on the concentration of 5-hydroxytryptamine in rat hippocampal dialysates in vivo. Neuropharmacology 1991, 30:1-4.
19. Bourin M., Hascoet M., Colombel M.C., Redrobe J.P., Baker G.B. Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotoninergic systems. Eur. Neuropsychopharmacol. 1996, 6:231-236.
20. Hasey G., Hanin I. The cholinergic-adrenergic hypothesis of depression reexamined using clonidine, metoprolol, and physostigmine in an animal model. Biol. Psychiatry 1991, 29:127-138.
21. Perona M.T., Waters S., Hall F.S., Sora I., Lesch K.P., Murphy D.L., et al. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav. Pharmacol. 2008, 19:566-574.
22. Gerstman B.B., Jolson H.M., Bauer M., Cho P., Livingston J.M., Platt R. The incidence of depression in new users of beta-blockers and selected antihypertensives. J. Clin. Epidemiol. 1996, 49:809-815.
23. Waldmeier P.C. Noradrenergic transmission in depression: under- or overfunction?. Pharmacopsychiatria 1981, 14:3-9.
24. Joyce P.R., Mulder R.T., McKenzie J.M., Luty S.E., Cloninger C.R. Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress. Anxiety 2004, 19:180-186.
25. Asnis G.M., McGinn L.K., Sanderson W.C. Atypical depression: clinical aspects and noradrenergic function. Am. J. Psychiatry 1995, 152:31-36.
26. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003, 28:1328-1335.
27. Louis W.J., Doyle A.E., Anavekar S.N. Plasma noradrenaline concentration and blood pressure in essential hypertension, phaeochromocytoma and depression. Clin. Sci. Mol. Med. Suppl. 1975, 2:S239-S242.
28. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
29. Aberg E., Fandino-Losada A., Sjoholm L.K., Forsell Y., Lavebratt C. The functional Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with depression and motivation in men from a Swedish population-based study. J. Affect. Disord. 2011, 129:158-166.
30. Haug E., Melle I., Andreassen O.A., Raballo A., Bratlien U., Oie M., et al. The association between anomalous self-experience and suicidality in first-episode schizophrenia seems mediated by depression. Compr. Psychiatry 2012, 53:456-460.
31. Davies D.L., Shepherd M. Reserpine in the treatment of anxious and depressed patients. Lancet 1955, 269:117-120.
32. Papakostas G.I. Evidence for S-adenosyl-l-methionine (SAM-e) for the treatment of major depressive disorder. J. Clin. Psychiatry 2009, 70(Suppl. 5):18-22.
33. Bailey K., Webster R., Baker A.L., Kavanagh D.J. Exposure to dysfunctional parenting and trauma events and posttraumatic stress profiles among a treatment sample with coexisting depression and alcohol use problems. Drug Alcohol Rev. 2012, 31:529-537.
34. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41:1-24.
35. Page M.E., Lucki I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 2002, 27:237-247.
36. Yoshino T., Nisijima K., Katoh S., Yui K., Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem. Int. 2002, 40:355-360.
37. Mundo E., Cattaneo E., Russo M., Altamura A.C. Clinical variables related to antidepressant-induced mania in bipolar disorder. J. Affect. Disord. 2006, 92:227-230.
38. Gao K., Kemp D.E., Ganocy S.J., Muzina D.J., Xia G., Findling R.L., et al. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord. 2008, 10:907-915.
39. Bhanji N.H., Margolese H.C., Saint-Laurent M., Chouinard G. Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'?. Int. Clin. Psychopharmacol. 2002, 17:319-322.
40. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
41. Kim K.W., Cox B.M. Inhibition of norepinephrine release from rat cortex slices by opioids: differences among agonists in sensitivities to antagonists suggest receptor heterogeneity. J. Pharmacol. Exp. Ther. 1993, 267:1153-1160.
42. 1 cannabinoid receptors on prefrontocortical norepinephrine release in the rat. Neuropharmacology 2012, 63:784-797.
43. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
44. Shouse M.N., Staba R.J., Saquib S.F., Farber P.R. Monoamines and sleep: microdialysis findings in pons and amygdala. Brain Res. 2000, 860:181-189.
45. Lena I., Parrot S., Deschaux O., Muffat-Joly S., Sauvinet V., Renaud B., et al. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J. Neurosci. Res. 2005, 81:891-899.
46. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STARD Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
47. Fitzgerald P.J. Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease?. Curr. Alzheimer Res. 2010, 7:506-516.
48. Fitzgerald P.J. Is elevated norepinephrine an etiological factor in some cases of epilepsy?. Seizure 2010, 19:311-318.
49. Fitzgerald P.J. Is norepinephrine an etiological factor in some types of cancer?. Int. J. Cancer 2009, 124:257-263.
50. Fitzgerald P.J. Is elevated noradrenaline an aetiological factor in a number of diseases?. Auton. Autacoid Pharmacol. 2009, 29:143-156.
51. Fitzgerald P.J. Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin. Epidemiol. 2010, 2:1-3.
52. Fitzgerald P.J. Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin. Epidemiol. 2012, 4:151-156.